## Extrazelluläre Vesikel – Zelltherapie der nächsten Generation


1. Raposo, G.; Stoorvogel, W., Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013, 200 (4), 373-83.
2. Yanez-Mo, M. et al., Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015, 4, 27066.
3. Kim, D. K. et al., EVpedia: a community web portal for extracellular vesicles research. Bioinformatics 2015, 31 (6), 933-9.
4. Lener, T. et al., Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles 2015, 4, 30087.
5. Harding, C.; Heuser, J.; Stahl, P., Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983, 97 (2), 329-39.
6. Pan, B. T.; Johnstone, R. M., Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33 (3), 967-78.
7. Pan, B. T. et al., Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985, 101 (3), 942-8.
8. Valadi, H. et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology 2007, 9 (6), 654-9.
9. van der Meel, R. et al., Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release 2014, 195, 72-85.
10. Johnsen, K. B. et al., A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta 2014, 1846 (1), 75-87.
11. Wiklander, O. P. et al., Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles 2015, 4, 26316.
12. El Andaloussi et al., Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013, 12 (5), 347-57.
13. Kanasty, R. et al., Delivery materials for siRNA therapeutics. Nat Mater 2013, 12 (11), 967-77.
14. Rankin-Turner, S. et al., A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos. Adv Drug Deliv Rev 2021, 173, 479-491.
15. Vader, P. et al., New considerations in the preparation of nucleic acid-loaded extracellular vesicles. Ther Deliv 2014, 5 (2), 105-7.
16. Wahlgren, J. et al., Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012, 40 (17), e130.
17. Cooper, J. M. et al., Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 2014, 29 (12), 1476-85.
18. Alvarez-Erviti, L. et al., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29 (4), 341-5.
19. Kooijmans, S. A. A. et al., Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release 2013, 172 (1), 229-238.
20. Ohno, S. et al., Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013, 21 (1), 185-91.
21. Zitvogel, L. et al., Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4 (5), 594-600.
22. Raposo, G. et al., B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183 (3), 1161-72.
23. Escudier, B. et al., Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 2005, 3 (1), 10.
24. Morse, M. A. et al., A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3 (1), 9.
25. Lamparski, H. G. et al., Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270 (2), 211-26.

26. Viaud, S. et al., Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J Immunother 2011, 34 (1), 65-75.

27. Besse, B.; et al., Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 2016, 5 (4), e1071008.

28. Kulp, A.; Kuehn, M. J., Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 2010, 64, 163-84.

29. Meckes, D. G., Jr.; Raab-Traub, N., Microvesicles and viral infection. J Virol 2011, 85 (24), 12844-54.

30. Marcilla, A. et al., Extracellular vesicles in parasitic diseases. J Extracell Vesicles 2014, 3, 25040.

31. Schorey, J. S.; Bhatnagar, S., Exosome function: from tumor immunology to pathogen biology. Traffic 2008, 9 (6), 871-81.

32. Rodrigues, M. L. et al., Vesicular transport systems in fungi. Future Microbiol 2011, 6 (11), 1371-81.

33. Kruh-Garcia, N. A. et al., Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. PLoS One 2014, 9 (7), e103811.

34. Kim, J. H. et al., Gram-negative and Gram-positive bacterial extracellular vesicles. Semin Cell Dev Biol 2015, 40, 97-104.

35. Oliveira, D. L. et al., Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun 2010, 78 (4), 1601-9.

36. Martin-Jaular, L. et al., Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections. PLoS One 2011, 6 (10), e26588.

37. Bhatnagar, S. et al., Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 2007, 110 (9), 3234-44.

38. Singh, P. P. et al., Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo. J Immunol 2012, 189 (2), 777-85.

39. Cheng, Y.; Schorey, J. S., Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection. Eur J Immunol 2013, 43 (12), 3279-90.

40. Holst, J.et al., Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27 Suppl 2, B3-12.

41. Carter, N. J., Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero((R))): a review of its use in primary and booster vaccination. BioDrugs 2013, 27 (3), 263-74.

42. Kim, O. Y. et al., Bacterial Protoplast-Derived Nanovesicles as Vaccine Delivery System against Bacterial Infection. Nano Lett 2015, 15 (1), 266-274.

43. Friedenstein, A. J. et al., Heterotopic of bone marrow.Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6 (2), 230-47.

44. Friedenstein, A. J. et al., Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974, 2 (2), 83-92.

45. Pittenger, M. F. et al., Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284 (5411), 143-47.

46. Kogler, G. et al., A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J.Exp.Med. 2004, 200 (2), 123.

47. Jiang, Y.et al., Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Experimental hematology 2002, 30 (8), 896-904.

48. Keating, A., Mesenchymal stromal cells: new directions. Cell stem cell 2012, 10 (6), 709-16.

49. Bianco, P. et al., The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature medicine 2013, 19 (1), 35-42.

50. Zuk, P. A. et al., Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13 (12), 4279-95.

51. Mareschi, K. et al., Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001, 86 (10), 1099-100.

52. Bianco, P.; Robey, P. G.; Simmons, P. J., Mesenchymal stem cells: revisiting history, concepts, and assays. Cell stem cell 2008, 2 (4), 313-9.

53. Erices, A.; Conget, P.; Minguell, J. J., Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109 (1), 235-42.

54. Di Nicola, M. et al., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99 (10), 3838-43.

55. Le Blanc, K.; Mougiakakos, D., Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012, 12 (5), 383-96.

56. Di Ianni, M. et al., Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008, 36 (3), 309-18.

57. Corcione, A. et al., A., Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107 (1), 367-72.

58. Selmani, Z. et al., Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26 (1), 212-22.

59. Casiraghi, F. et al., Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181 (6), 3933-46.

60. Adutler-Lieber, S. et al., Human macrophage regulation via interaction with cardiac adipose tissue-derived mesenchymal stromal cells. J Cardiovasc Pharmacol Ther 2013, 18 (1), 78-86.

61. Lai, R. C. et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem cell research 2010, 4 (3), 214-22.

62. Kordelas, L et al., MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28 (4), 970-3.

63. Lee, R. H. et al., Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell stem cell 2009, 5 (1), 54-63.

64. Schrepfer, S. et al., Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39 (2), 573-6.

65. Gao, J. et al., The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169 (1), 12-20.

66. Timmers, L. et al., Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007, 1 (2), 129-37.

67. Gnecchi, M. et al., Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11 (4), 367-8.

68. Gnecchi, M. et al., Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006, 20 (6), 661-9.

69. Bruno, S. et al., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20 (5), 1053-67.

70. Herrera, M. B. et al., Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell Mol Med 2010, 14 (6B), 1605-18.

71. Li, T. et al., Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 2013, 22 (6), 845-54.

72. Tan, C. Y. et al., Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther 2014, 5 (3), 76.

73. Lee, C. et al., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126 (22), 2601-11.

74. Zhang, B. et al., Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev 2014, 23 (11), 1233-44.

75. Zhang, B. et al., HucMSC-Exosome Mediated-Wnt4 Signaling Is Required for Cutaneous Wound Healing. Stem Cells 2015, 33 (7), 2158-68.

76. Zhang, H. C. et al., Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev 2012, 21 (18), 3289-97.

77. Hsieh, J. Y. et al., Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 2013, 8 (8), e72604.

78. Xin, H. et al., Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab 2013, 33 (11), 1711-5.

79. Raisi, A. et al., The mesenchymal stem cell-derived microvesicles enhance sciatic nerve regeneration in rat: a novel approach in peripheral nerve cell therapy. J Trauma Acute Care Surg 2014, 76 (4), 991-7.

80. Buonocore, G. et al., New pharmacological approaches in infants with hypoxic-ischemic encephalopathy. Curr Pharm Des 2012, 18 (21), 3086-100.

81. Doeppner, T. R. et al., Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med 2015, 4 (10), 1131-43.

82. Gortner, L. et al., Regenerative therapies in neonatology: clinical perspectives. Klin Padiatr 2012, 224 (4), 233-40.

83. Jellema, R. K. et al., Mesenchymal stem cells induce T-cell tolerance and protect the preterm brain after global hypoxia-ischemia. PLoS One 2013, 8 (8), e73031.

84. Donega, V. et al., Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury. Exp Neurol 2014, 261, 53-64.

85. van Velthoven, C. T. et al., Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J Neurosci 2010, 30 (28), 9603-11.

86. Ophelders, D. R. et al., Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl Med 2016, 5 (6), 754-63.

87. Drommelschmidt, K. et al., Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. Brain Behav Immun 2017, 60, 220-232.

88. Gussenhoven, R. et al., Annexin A1 as Neuroprotective Determinant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-Ischemic Encephalopathy. J Clin Med 2019, 8 (2).

89. Kaminski, N. et al., Mesenchymal Stromal Cell-Derived Extracellular Vesicles Reduce Neuroinflammation, Promote Neural Cell Proliferation and Improve Oligodendrocyte Maturation in Neonatal Hypoxic-Ischemic Brain Injury. Front Cell Neurosci 2020, 14, 601176.

90. Gregorius, J. et al., Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice. Basic Res Cardiol 2021, 116 (1), 40.

91. Wang, C. et al., Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Induce Ischemic Neuroprotection by Modulating Leukocytes and Specifically Neutrophils. Stroke 2020, 51 (6), 1825-1834.

92. Rivera, F. J.; Aigner, L., Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis. Biological Research 2012, 45 (3), 257-268.

93. Katsuda, T. et al., Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci Rep 2013, 3, 1197.

94. Clayton, A. et al., Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011, 187 (2), 676-83.

95. Schuler, P. J. et al., Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 2014, 177 (2), 531-43.

96. Eltzschig, H. K.; Sitkovsky, M. V.; Robson, S. C., Purinergic signaling during inflammation. N Engl J Med 2012, 367 (24), 2322-33.

97. Idzko, M.; Ferrari, D.; Eltzschig, H. K., Nucleotide signalling during inflammation. Nature 2014, 509 (7500), 310-7.

98. Deaglio, S. et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204 (6), 1257-65.

99. Dwyer, K. M. et al., CD39 and control of cellular immune responses. Purinergic Signal 2007, 3 (1-2), 171-80.

100. Amarnath, S. et al., Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells 2015, 33 (4), 1200-12.

101. Nery, A. A. et al., Human mesenchymal stem cells: from immunophenotyping by flow cytometry to clinical applications. Cytometry A 2013, 83 (1), 48-61.

102. Romanelli, P. et al., Extracellular Vesicles Can Deliver Anti-inflammatory and Anti-scarring Activities of Mesenchymal Stromal Cells After Spinal Cord Injury. Front Neurol 2019, 10, 1225.

103. Warnecke, A. et al., Extracellular vesicles from human multipotent stromal cells protect against hearing loss after noise trauma in vivo. Clin Transl Med 2020, 10 (8), e262.

104. Warnecke, A. et al., First-in-human intracochlear application of human stromal cell-derived extracellular vesicles. J Extracell Vesicles 2021, 10 (8), e12094.

105. Laner-Plamberger, S. et al., Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate. J Transl Med 2015, 13, 354.

106. Gimona, M. et al., Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use. Int J Mol Sci 2017, 18 (6).

107. Pachler, K. et al., A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy 2017, 19 (4), 458-472.

108. Rohde, E.; Pachler, K.; Gimona, M., Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing. Cytotherapy 2019, 21 (6), 581-592.

109. Gimona, M. et al., Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy 2021, 23 (5), 373-380.

110. Fais, S. et al., Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano 2016, 10 (4), 3886-99.

111. Reiner, A. T. et al., Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles. Stem Cells Transl Med 2017, 6 (8), 1730-1739.

112. Thery, C. et al., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018, 7 (1), 1535750.

113. Pachler, K. et al., An In Vitro Potency Assay for Monitoring the Immunomodulatory Potential of Stromal Cell-Derived Extracellular Vesicles. Int J Mol Sci 2017, 18 (7).

114. Witwer, K. W. et al., Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles 2019, 8 (1), 1609206.

115. Borger, V. et al., International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy 2020, 22 (9), 482-485.

116. Lim, S. K. et al., Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al. Stem Cells Dev 2020, 29 (14), 877-878.

117. Weiss, D. J. et al., Weiss Response to Sengupta et al. (DOI: 10.1089/scd.2020.0095). Stem Cells Dev 2020, 29 (24), 1533-1534.